摘要
目的观察HER4在胶质瘤中的表达情况,分析HER4表达与胶质瘤患者临床病理参数及预后的相关性。方法用免疫组织化学法和免疫印迹技术检测88例胶质瘤和14例正常脑组织中HER4的表达;结合临床资料分析HER4表达与胶质瘤患者临床病理参数的关系并比较HER4阳性与阴性患者的无复发生存率。结果免疫组化结果显示:胶质瘤与正常脑组织相比存在HER4的高表达(P <0. 05);免疫印迹结果显示:胶质瘤内的HER4蛋白含量高于正常脑组织(P <0. 05),且随肿瘤病理级别的增加HER4水平逐渐增高(P <0. 05); HER4的表达与患者性别、年龄、肿瘤大小、KPS评分及临床分期无明显相关(P> 0. 05),而与胶质瘤的病理分级明显相关(P <0. 05); HER4阳性表达组的3年及5年无复发生存率均显著低于HER4阴性表达组(P <0. 05)。结论 HER4可能是胶质瘤生长的重要调控基因,并与其恶性进展有关; HER4可成为评价胶质瘤预后的一个新生物学指标。
Objective To observe the expression of HER4 in gliomas,and analyze the correlation of HER4 expression with clinicopathological parameters and prognosis of gliomas patients.Methods Detected the expression level of HER4 in 88 cases of gliomas and 14 cases of normal brain tissue by Immunohistochemistry and Western blot;Combined with clinical data,analysis the relationship between HER4 expression and clinicopathological parameters of gliomas patients and compare the relapse free survival between HER4 positive and negative patients. Results Immunohistochemistry analysis showed that HER4 highly expressed in gliomas compared with normal brain tissue (P<0.05);Western blot analysis showed that the expression level of HER4 in gliomas was significantly higher than that of normal brain tissue (P<0.05),and a gradually increased expression of HER4 in vary pathologic grading (grade Ⅰ,Ⅱ,Ⅲ,Ⅳ)gliomas was also observed (P<0.05 ). The expression of HER4 was not significantly associated with patients' gender,age,tumor size,KPS score and clinical stage (P>0.05),but was significantly correlated with pathological grade of gliomas (P<0.05);3 years and 5 years relapse free survival of the HER4 positive group were significantly lower than that of the negative group (P<0.05). Conclusions HER4 may be an important regulator gene for gliomas growth and related to its malignant progression. HER4 can be a new biological indicator for evaluating the prognosis of gliomas.
作者
张新鹃
孙龙
王海凤
张彩坤
邢冬杰
ZHANG Xin-juan;SUN Long;WANG Hai-feng(Department of Western Medicine Education,Shandong College of Traditional Chinese Medicine,Yantai 264199,China)
出处
《临床神经病学杂志》
CAS
2018年第6期405-408,共4页
Journal of Clinical Neurology
基金
山东省高等学校科技计划项目(J16LL59)
